Does nitric oxide inhalation need to be reassessed?
DOI:
https://doi.org/10.21649/akemu.v12i1.822Keywords:
Nitric Oxide. Respiratory Distress Syndrome, Newborn. Endothelium-Dependent Relaxing Factors. Persistent Fetal Circulation Syndrome. Bronchopulmonary Dysplasia. Pharmaceutical Preparations. Bronchodilator Agents. Administration, Inhalation. CyclicAbstract
Background: Inhaled nitric oxide is a drug which has been given FDA approval in 1999 but was not found prior to approval to be safe for use in premature neonates. Aim: To review and assess the studies which was done prior to its approval in order to find out what evidences the approval by the FDA was based on. Methods: A thorough search of the electronic data-base, Medline, Embase, Cinahl, Google. Conclusion: The use of this drug in treatment of the Pulmonary hypertension in premature babies is still contraversial and hold a serious untoward effects on the health, it should only used as the last ditch.Downloads
Published
03/21/2016
How to Cite
Dahiyat, K. A. (2016). Does nitric oxide inhalation need to be reassessed?. Annals of King Edward Medical University, 12(1). https://doi.org/10.21649/akemu.v12i1.822
Issue
Section
Research Articles
License
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk